The accelerated aging model reveals critical mechanisms of late-onset Parkinson’s disease
Tóm tắt
Late-onset Parkinson’s disease (LOPD) is a common neurodegenerative disorder and lacks disease-modifying treatments, attracting major attentions as the aggravating trend of aging population. There were numerous evidences supported that accelerated aging was the primary risk factor for LOPD, thus pointed out that the mechanisms of PD should be revealed thoroughly based on aging acceleration. However, how PD was triggered by accelerated aging remained unclear and the systematic prediction model was needed to study the mechanisms of PD.
In this paper, an improved PD predictor was presented by comparing with the normal aging process, and both aging and PD markers were identified herein using machine learning methods. Based on the aging scores, the aging acceleration network was constructed thereby, where the enrichment analysis shed light on key characteristics of LOPD. As a result, dysregulated energy metabolisms, the cell apoptosis, neuroinflammation and the ion imbalances were identified as crucial factors linking accelerated aging and PD coordinately, along with dysfunctions in the immune system.
In short, mechanisms between aging and LOPD were integrated by our computational pipeline.
Từ khóa
Tài liệu tham khảo
Xicoy H, Peñuelas N, Vila M, Laguna A. Autophagic- and lysosomal-related biomarkers for Parkinson’s disease: lights and shadows. Cells. 2019;8(11):1317.
Delenclos M, Jones DR, McLean PJ, Uitti RJ. Biomarkers in Parkinson’s disease: advances and strategies. Parkinsonism Relat Disord. 2016;22:S106–10.
Collier TJ, Kanaan NM, Kordower JH. Aging and Parkinson’s disease: different sides of the same coin? Mov Disord. 2017;32(7):983–90.
Frisardi V, Santamato A, Cheeran B. Parkinson’s disease: new insights into pathophysiology and rehabilitative approaches. Parkinsons Dis. 2016;2016:3121727.
Bobela W, Aebischer P, Schneider BL. Αlpha-synuclein as a mediator in the interplay between aging and Parkinson’s disease. Biomolecules. 2015;5(4):2675–700.
Liu J, Liu W, Lu Y, Tian H, Duan C, Lu L, Gao G, Wu X, Wang X, Yang H. Piperlongumine restores the balance of autophagy and apoptosis by increasing BCL2 phosphorylation in rotenone-induced Parkinson disease models. Autophagy. 2018;14(5):845–61.
Argüelles S, Guerrero-Castilla A, Cano M, Muñoz MF, Ayala A. Advantages and disadvantages of apoptosis in the aging process. Ann N Y Acad Sci. 2019;1443(1):20–33.
Calabrese V, Santoro A, Monti D, Crupi R, Di Paola R, Latteri S, Cuzzocrea S, Zappia M, Giordano J, Calabrese EJ, Franceschi C. Aging and Parkinson’s disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radic Biol Med. 2018;115:80–91.
Rudow G, O'Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, Marsh L, Dawson TM, Crain BJ, West MJ, Troncoso JC. Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol. 2008;115(4):461–70.
Chesnokova AY, Ekimova IV, Pastukhov YF. Parkinson’s disease and aging. Adv Gerontol. 2018;31(5):668–78.
Lahmiri S, Dawson DA, Shmuel A. Performance of machine learning methods in diagnosing Parkinson’s disease based on dysphonia measures. Biomed Eng Lett. 2018;8(1):29–39.
Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, Wuest DM, Church BW, Khalil IG, Hayete B, Venuto CS. Large-scale identification of clinical and genetic predictors of Parkinson’s disease motor progression in newly-diagnosed patients: a longitudinal cohort study and validation. Lancet Neurol. 2017;16(11):908–16.
Lahmiri S, Shmuel A. Detection of Parkinson’s disease based on voice patterns ranking and optimized support vector machine. Biomed Signal Process Control. 2019;49:427–33.
Lahmiri S. Gait nonlinear patterns related to Parkinson's disease and age. IEEE Trans Instrum Meas. 2018;68(7):2545–51.
Sood S, Gallagher IJ, Lunnon K, Rullman E, Keohane A, Crossland H, Phillips BE, Cederholm T, Jensen T, van Loon LJC, Lannfelt L, Kraus WE, Atherton PJ, Howard R, Gustafsson T, Hodges A, Timmons JA. A novel multi-tissue rna diagnostic of healthy ageing relates to cognitive health status. Genome Biol. 2015;16(1):185.
Hubberten M, Bochenek G, Chen H, Häsler R, Wiehe R, Rosenstiel P, Jepsen S, Dommisch H, Schaefer AS. Linear isoforms of the long noncoding RNA CDKN2B-AS1 regulate the c-myc-enhancer binding factor RBMS1. Eur J Hum Genet. 2019;27(1):80–9.
Yin M, Lü M, Yao G, Tian H, Lian J, Liu L, Liang M, Wang Y, Sun F. Transactivation of microRNA-383 by steroidogenic factor-1 promotes estradiol release from mouse ovarian granulosa cells by targeting RBMS1. Mol Endocrinol. 2012;26(7):1129–43.
Kirkland JL, Tchkonia T. Cellular senescence: a translational perspective. EBioMedicine. 2017;21:21–8.
Liu CM, Hsu WH, Lin WY, Chen HC. Adducin family proteins possess different nuclear export potentials. J Biomed Sci. 2017;24(1):30.
Kiang KM, Leung GK. A review on adducin from functional to pathological mechanisms: future direction in cancer. Biomed Res Int. 2018;2018:3465929.
Ludtmann MHR, Abramov AY. Mitochondrial calcium imbalance in Parkinson's disease. Neurosci Lett. 2018;663:86–90.
Cappello AR, Curcio R, Lappano R, Maggiolini M, Dolce V. The physiopathological role of the exchangers belonging to the SLC37 family. Front Chem. 2018;6:122.
Nakano M, Imamura H, Sasaoka N, Yamamoto M, Uemura N, Shudo T, Fuchigami T, Takahashi R, Kakizuka A. ATP maintenance via two types of ATP regulators mitigates pathological phenotypes in mouse models of Parkinson’s disease. EBioMedicine. 2017;22:225–41.
Zhao L, Zheng X, Liu J, Zheng R, Yang R, Wang Y, Sun L. PPAR signaling pathway in the first trimester placenta from in vitro fertilization and embryo transfer. Biomed Pharmacother. 2019;118:109251.
Burgaz S, García C, Gómez-Cañas M, Muñoz E, Fernández-Ruiz J. Development of an oral treatment with the PPAR-γ-acting cannabinoid VCE-003.2 against the inflammation-driven neuronal deterioration in experimental Parkinson’s disease. Molecules. 2019;24(15):2702.
Machado MMF, Bassani TB, Cóppola-Segovia V, Moura ELR, Zanata SM, Andreatini R, Vital MABF. PPAR-γ agonist pioglitazone reduces microglial proliferation and NF-κB activation in the Substantia Nigra in the 6-hydroxydopamine model of Parkinson’s disease. Pharmacol Rep. 2019;71(4):556–64.
Chaturvedi RK, Beal MF. PPAR-γ: therapeutic prospects in Parkinson’s disease. J Neurochem. 2008;106(2):506–18.
Corona JC, Duchen MR. PPARγ and PGC-1α as therapeutic targets in Parkinson’s. Neurochem Res. 2015;40(2):308–16.
Fiszer U, Mix E, Fredrikson S, Kostulas V, Link H. Parkinson’s disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol Scand. 1994;90(3):160–6.
Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, Liong C, McMurtrey C, Hildebrand WH, Mao X, Dawson VL, Dawson TM, Oseroff C, Pham J, Sidney J, Dillon MB, Carpenter C, Weiskopf D, Phillips E, Mallal S, Peters B, Frazier A, Lindestam Arlehamn CS, Sette A. T cells of Parkinson’s disease patients recognize α–synuclein peptides. Nature. 2017;546(7660):656–61.
Fyfe I. Parkinson disease: T cells recognize α-Synuclein peptides in Parkinson disease. Nat Rev Neurol. 2017;13(8):450–1.
Błaszczyk JW. The emerging role of energy metabolism and neuroprotective strategies in Parkinson’s disease. Front Aging Neurosci. 2018;10:301.
Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017;36(11):1474–92.
Lessel D, Gehbauer C, Bramswig NC, Schluth-Bolard C, Venkataramanappa S, van Gassen KLI, Hempel M, Haack TB, Baresic A, Genetti CA, Funari MFA, Lessel I, Kuhlmann L, Simon R, Liu P, Denecke J, Kuechler A, de Kruijff I, Shoukier M, Lek M, Mullen T, Lüdecke HJ, Lerario AM, Kobbe R, Krieger T, Demeer B, Lebrun M, Keren B, Nava C, Buratti J, Afenjar A, Shinawi M, Guillen Sacoto MJ, Gauthier J, Hamdan FF, Laberge AM, Campeau PM, Louie RJ, Cathey SS, Prinz I, Jorge AAL, Terhal PA, Lenhard B, Wieczorek D, Strom TM, Agrawal PB, Britsch S, Tolosa E, Kubisch C. BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells. Brain. 2018;141(8):2299–311.
Fang D, Cui K, Hu G, Gurram RK, Zhong C, Oler AJ, Yagi R, Zhao M, Sharma S, Liu P, Sun B, Zhao K, Zhu J. Bcl11b, a novel GATA3-interacting protein, suppresses Th1 while limiting Th2 cell differentiation. J Exp Med. 2018;215(5):1449–62.
Lennon MJ, Jones SP, Lovelace MD, Guillemin GJ, Brew BJ. Bcl11b-a critical neurodevelopmental transcription factor-roles in health and disease. Front Cell Neurosci. 2017;11:89.
Patel R, Sesti F. Oxidation of ion channels in the aging nervous system. Brain Res. 2016;1639:174–85.
Kutyavin VI, Chawla A. BCL6 regulates brown adipocyte dormancy to maintain thermogenic reserve and fitness. Proc Natl Acad Sci U S A. 2019;116(34):17071–80.
Pinti M, Appay V, Campisi J, Frasca D, Fülöp T, Sauce D, Larbi A, Weinberger B, Cossarizza A. Aging of the immune system: focus on inflammation and vaccination. Eur J Immunol. 2016;46(10):2286–301.
Barrientos RM, Frank MG, Watkins LR, Maier SF. Aging-related changes in neuroimmune-endocrine function: implications for hippocampal-dependent cognition. Horm Behav. 2012;62(3):219–27.
Dzamko N, Geczy CL, Halliday GM. Inflammation is genetically implicated in Parkinson's disease. Neuroscience. 2015;302:89–102.
Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H, Zaheer S, Iyer SS, Zaheer A. Neuroinflammation Induces Neurodegeneration. J Neurol Neurosurg Spine. 2016;1(1):1003.
Duda J, Pötschke C, Liss B. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson’s disease. J Neurochem. 2016;139(Suppl 1):156–78.
Liang Z, Zhao Y, Ruan L, Zhu L, Jin K, Zhuge Q, Su DM, Zhao Y. Impact of aging immune system on neurodegeneration and potential immunotherapies. Prog Neurobiol. 2017;157:2–28.